Every material Form 8-K Aura Biosciences, Inc. has filed with the SEC since May 11, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Aura Biosciences reported third quarter 2026 results, with a net loss of $32.1 million, up from $26.1 million a year earlier. The company said a $4.5 million restructuring charge, tied to its reorganization around its ocular oncology portfolio, contributed to higher general and administrative expenses, and it reiterated that its cash is expected to last into the first half of 2029.
Net loss of $32.1 million for the quarter ended September 30, 2026, versus $26.1 million a year earlier; loss per share was $0.29, versus $0.40.
General and administrative expenses rose to $10.3 million from $5.7 million, driven mainly by restructuring charges of approximately $4.5 million.
Research and development expenses rose to $24.7 million from $22.2 million, tied to the Phase 3 CoMpass trial.
Cash, cash equivalents and marketable securities totaled $297.2 million as of September 30, 2026.
Aura Biosciences reported a second-quarter 2026 net loss of $45.6 million, up from $27.0 million a year earlier, and announced a restructuring that includes a workforce reduction of approximately 20% and a minimal shift of resources away from its bladder cancer program. The company estimates restructuring costs of $2.9 million to $3.2 million and says its cash runway now extends into the first half of 2029, but its chief financial and business officer is departing, which adds leadership change to a wider loss.
Q2 2026 net loss was $45.6 million, versus $27.0 million in Q2 2025; R&D expenses rose to $30.7 million and G&A to $17.3 million, including $10.3 million of stock-based compensation.
Workforce reduction of approximately 20%; estimated restructuring costs of $2.9 million to $3.2 million, with most expected to be paid in Q3 2026.
Cash, cash equivalents and marketable securities totaled $323.8 million as of June 30, 2026, which the company says funds operations into 1H 2029.
Anthony Gibney, Chief Financial and Business Officer, departs effective September 1, 2026; Susan Abu-Absi began as Chief Operating Officer on August 10, 2026.
Aura Biosciences expanded its board from six to seven directors and appointed Jeremy Bender as an independent Class II director effective July 7, 2026. The filing also discloses an amended director compensation policy, adopted June 11, 2026, that raised the equity awards for new and continuing non-employee directors.
Jeremy Bender, Ph.D., M.B.A., is appointed to fill the newly created seat; his term expires at the 2029 annual meeting of stockholders.
Dr. Bender joins the Compensation Committee and the Nominating and Corporate Governance Committee, effective July 7, 2026.
His initial awards are a stock option for 60,000 shares and an RSU award for 30,000 shares, vesting in equal annual installments over three years.
On June 11, 2026, the annual option award for continuing non-employee directors was raised from 17,000 to 30,000 shares, and the annual RSU award from 13,000 to 15,000 shares.
Aura Biosciences reported first quarter 2026 results, with a net loss of $33.7 million, up from $27.5 million a year earlier. The loss per share narrowed to $0.50 from $0.55, and the company said a $280.8 million net-proceeds stock offering completed May 5, 2026, should fund operations into the second half of 2028.
Net loss was $33.7 million for the quarter ended March 31, 2026, versus $27.5 million a year earlier; basic and diluted loss per share was $0.50 versus $0.55.
Research and development expenses rose to $28.0 million from $23.3 million, mainly due to the Phase 3 CoMpass trial in early choroidal melanoma.
Cash, cash equivalents and marketable securities were $114.7 million at March 31, 2026, before the offering; about $39.0 million of offering proceeds was used to repurchase shares held by Matrix Capital Management Master Fund, LP.
Natalie Holles became Chief Executive Officer and President effective April 30, 2026, succeeding founder Elisabet de los Pinos, Ph.D.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Aura Biosciences, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →